Johnson & Johnson plans to go ahead with a $2.3 billion cash offer to acquire the rest of Crucell. The drug giant has left open a possibility for renegotiation in case the biotech firm's manufacturing problems in South Korea worsen. J&J expects Dutch regulators to decide on the transaction ahead of Crucell's shareholder meeting Dec. 10.

Related Summaries